Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone732-537-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$2.52 billion
Profitability
Miscellaneous
Employees12,300
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable
Catalent (NYSE:CTLT) Frequently Asked Questions
What is Catalent's stock symbol?
Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."
How were Catalent's earnings last quarter?
Catalent Inc (NYSE:CTLT) released its quarterly earnings data on Tuesday, August, 27th. The company reported $0.65 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.62 by $0.03. The firm had revenue of $725.70 million for the quarter, compared to analyst estimates of $719.20 million. Catalent had a net margin of 5.46% and a return on equity of 15.89%. The business's quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.67 earnings per share. View Catalent's Earnings History.
When is Catalent's next earnings date?
How can I listen to Catalent's earnings call?
Catalent will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Catalent issued on next quarter's earnings?
Catalent updated its FY20 earnings guidance on Tuesday, August, 27th. The company provided earnings per share (EPS) guidance of ~$1.89-2.06 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.98. The company issued revenue guidance of $2.78-2.88 billion, compared to the consensus revenue estimate of $2.84 billion.
What price target have analysts set for CTLT?
7 analysts have issued 1-year price objectives for Catalent's shares. Their predictions range from $45.00 to $64.00. On average, they expect Catalent's share price to reach $56.71 in the next year. This suggests a possible upside of 16.6% from the stock's current price. View Analyst Price Targets for Catalent.
What is the consensus analysts' recommendation for Catalent?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Catalent.
Has Catalent been receiving favorable news coverage?
News stories about CTLT stock have been trending somewhat positive on Monday, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalent earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Catalent.
Who are some of Catalent's key competitors?
Some companies that are related to Catalent include Takeda Pharmaceutical (TKPYY), Alexion Pharmaceuticals (ALXN), Merck KGaA (MKGAF), UCB (UCBJF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), BioMarin Pharmaceutical (BMRN), Array Biopharma (ARRY), Mylan (MYL), Elanco Animal Health (ELAN), Ono Pharmaceutical (OPHLF), Alnylam Pharmaceuticals (ALNY), GALAPAGOS NV/S (GLPG), Teva Pharmaceutical Industries (TEVA) and Bausch Health Companies (BHC).
What other stocks do shareholders of Catalent own?
Who are Catalent's key executives?
Catalent's management team includes the folowing people:
- Mr. John R. Chiminski, Chairman & CEO (Age 55)
- Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
- Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
- Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
- Mr. Alessandro Maselli, Pres & COO (Age 47)
Who are Catalent's major shareholders?
Catalent's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Envestnet Asset Management Inc. (0.08%), Mountain Pacific Investment Advisers Inc. ID (0.08%), Brinker Capital Inc. (0.04%), Pacer Advisors Inc. (0.04%), Meeder Asset Management Inc. (0.02%) and State of Alaska Department of Revenue (0.02%). Company insiders that own Catalent stock include Aristippos Gennadios, Barry Littlejohns, Donald E Morel, Jr, Gregory T Lucier, John J Greisch, John R Chiminski, Lance Miyamoto, Peter L Buzy, Steven L Fasman, Uwe Roehrhoff and William Downie. View Institutional Ownership Trends for Catalent.
Which major investors are selling Catalent stock?
CTLT stock was sold by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC, Oakbrook Investments LLC, Pacer Advisors Inc., Crossmark Global Holdings Inc. and First Bank & Trust. Company insiders that have sold Catalent company stock in the last year include Aristippos Gennadios, Barry Littlejohns, John R Chiminski, Lance Miyamoto, Steven L Fasman and William Downie. View Insider Buying and Selling for Catalent.
Which major investors are buying Catalent stock?
CTLT stock was acquired by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., State of Alaska Department of Revenue, Brinker Capital Inc., Meeder Asset Management Inc., Campbell & CO Investment Adviser LLC, Mountain Pacific Investment Advisers Inc. ID, Strs Ohio and We Are One Seven LLC. Company insiders that have bought Catalent stock in the last two years include Donald E Morel, Jr, Gregory T Lucier, John J Greisch, Peter L Buzy and Uwe Roehrhoff. View Insider Buying and Selling for Catalent.
How do I buy shares of Catalent?
Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Catalent's stock price today?
One share of CTLT stock can currently be purchased for approximately $48.63.
How big of a company is Catalent?
Catalent has a market capitalization of $7.11 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe.View Additional Information About Catalent.
What is Catalent's official website?
How can I contact Catalent?
Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]
MarketBeat Community Rating for Catalent (NYSE CTLT)
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
